Sermorelin is a synthetic peptide that represents the 1–29 amino acid fragment of growth hormone–releasing hormone (GHRH). It is studied for its ability to stimulate endogenous growth hormone (GH) release by activating the body’s natural regulatory pathways.
Rather than supplying growth hormone directly, Sermorelin signals the pituitary gland to produce and release GH in a physiologic, pulsatile manner.
Sermorelin binds to GHRH receptors located on the anterior pituitary gland.
This interaction:
Stimulates synthesis and release of growth hormone
Preserves natural feedback loops
Follows normal GH pulse timing rather than sustained elevation
Because it works upstream, Sermorelin relies on intact pituitary function to exert its effects in research models.
Encourages natural GH release rather than replacing it
Supports physiologic pulsatility patterns
Acts through hypothalamic–pituitary signaling
Useful for studying GH axis responsiveness
GH release may secondarily influence IGF-1 production
Effects are indirect and regulated, not forced
Less suppressive to natural GH production compared to exogenous GH in research settings
Important distinctions:
❌ Not growth hormone itself
❌ Not a ghrelin mimetic (unlike GHRPs such as GHRP-2 or GHRP-6)
❌ Not long-acting or continuously active
Instead, Sermorelin operates through GHRH-specific signaling, making it more physiologic in GH-axis research.
